AR and prostate cancer: The major focus for prostate cancer therapeutics has been to reduce androgen levels through androgen deprivation therapy (ADT), either with inhibitors of androgen synthesis (for example, abiraterone) or with antagonists that prevent androgen binding to the AR (such as bicalutamide or enzalutamide)24.